Bispecific anti-PD-1/CTLA-4 antibody for advanced solid tumors

被引：7

作者：

Perez-Santos, Martin ^{[1
]}

机构：

[1] Benemerita Univ Autonoma Puebla, Direcc Innovac & Transferencia Conocimiento, Puebla 72570, Mexico

来源：

PHARMACEUTICAL PATENT ANALYST | 2020年 / 9卷 / 05期

关键词：

bispecific; cancer; CTLA-4; immunotherapy; patent; PD-1; PEMBROLIZUMAB; CANCER; IPILIMUMAB; THERAPY; PATHWAY;

D O I：

10.4155/ppa-2020-0017

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

PD-1 and CTLA-4 are checkpoint inhibitors of the immune response in cancer, making them the target molecules for the development of therapeutic antibodies. US2019161548 patent describes a bispecific antibody capable of specifically binding to PD-1 and CTLA-4 that induced the proliferation and activation of CD8(+)cells, as well as the expression of induclble co-stimulator in CD4(+)T cells. Clinical trials to evaluate safety, dose-limiting toxicities and maximum tolerated/administered dose are still in the patient recruitment phase, but it will be of great interest to the scientific and medical community to know if the first bispecific anti-PD-1/CLTA-4 antibody, exceeds expectations and exceeds action of the combination of nivolumab and epilimumab in the treatment of cancer.

引用

页码：149 / 154

页数：6

共 37 条

[1]

AKESO BIOPHARMA, 2019, [No title captured], Patent No. [US2019185569, 2019185569]

[2]

Bajwa Ravneet, 2019, J Clin Med Res, V11, P225, DOI 10.14740/jocmr3750

[3] CTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer [J].

Bengsch, Fee ;

Knoblock, Dawson M. ;

Liu, Anni ;

McAllister, Florencia ;

Beatty, Gregory L. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2017, 66 (12) :1609-1617

[4]

BIOMED VALLEY DISCOVERIES, 2016, [No title captured], Patent No. [US2016145355, 2016145355]

[5]

BRISTOL-MYERS SQUIBB, 2019, [No title captured], Patent No. [US10512689B2, 10512689]

[6] Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [J].

Burtness, Barbara ;

Harrington, Kevin J. ;

Greil, Richard ;

Soulieres, Denis ;

Tahara, Makoto ;

de Castro, Gilberto, Jr. ;

Psyrri, Amanda ;

Baste, Neus ;

Neupane, Prakash ;

Bratland, Ase ;

Fuereder, Thorsten ;

Hughes, Brett G. M. ;

Mesia, Ricard ;

Ngamphaiboon, Nuttapong ;

Rordorf, Tamara ;

Ishak, Wan Zamaniah Wan ;

Hong, Ruey-Long ;

Mendoza, Rene Gonzalez ;

Roy, Ananya ;

Zhang, Yayan ;

Gumuscu, Burak ;

Cheng, Jonathan D. ;

Jin, Fan ;

Rischin, Danny .

LANCET, 2019, 394 (10212) :1915-1928

[7] PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma [J].

Cao, Jinfeng ;

Brouwer, Niels J. ;

Richards, Kate E. ;

Marinkovic, Marina ;

van Duinen, Sjoerd ;

Hurkmans, Daan ;

Verdegaal, Els M. E. ;

Jordanova, Ekaterina S. ;

Jager, Martine J. .

ONCOTARGET, 2017, 8 (33) :54722-54734

[8] Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial [J].

Carlino, Matteo S. ;

Long, Georgina V. ;

Schadendorf, Dirk ;

Robert, Caroline ;

Ribas, Antoni ;

Richtig, Erika ;

Nyakas, Marta ;

Caglevic, Christian ;

Tarhini, Ahmed ;

Blank, Christian ;

Hoeller, Christoph ;

Bar-Sela, Gil ;

Barrow, Catherine ;

Wolter, Pascal ;

Zhou, Honghong ;

Emancipator, Kenneth ;

Jensen, Erin H. ;

Ebbinghaus, Scot ;

Ibrahim, Nageatte ;

Daud, Adil .

EUROPEAN JOURNAL OF CANCER, 2018, 101 :236-243

[9] Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087 [J].

Chen, Robert ;

Zinzani, Pier Luigi ;

Lee, Hun Ju ;

Armand, Philippe ;

Johnson, Nathalie A. ;

Brice, Pauline ;

Radford, John ;

Ribrag, Vincent ;

Molin, Daniel ;

Vassilakopoulos, Theodoros P. ;

Tomita, Akihiro ;

von Tresckow, Bastian ;

Shipp, Margaret A. ;

Lin, Jianxin ;

Kim, Eunhee ;

Nahar, Akash ;

Balakumaran, Arun ;

Moskowitz, Craig H. .

BLOOD, 2019, 134 (14) :1144-1153

[10] CTLA-4 positive breast cancer cells suppress dendritic cells maturation and function [J].

Chen, Xi ;

Shao, Qianqian ;

Hao, Shengnan ;

Zhao, Zhonghua ;

Wang, Yang ;

Guo, Xiaofan ;

He, Ying ;

Gao, Wenjuan ;

Mao, Haiting .

ONCOTARGET, 2017, 8 (08) :13703-13715

← 1 2 3 4 →